Ignite Creation Date:
2024-05-06 @ 6:27 PM
Last Modification Date:
2024-10-26 @ 2:48 PM
Study NCT ID:
NCT05673057
Status:
RECRUITING
Last Update Posted:
2024-01-24
First Post:
2022-12-14
Brief Title:
Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Sponsor:
Molecular Partners AG
Organization:
Molecular Partners AG
Study Overview
Official Title:
A Phase 12a First-in-human Open-label Multicenter Dose Escalation Study of MP0533 in Patients With RelapsedRefractory RR Acute Myeloid Leukemia AML or Myelodysplastic Syndrome MDS
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety tolerability and preliminary activity of MP0533 in patients with relapsedrefractory acute myeloid leukemia AML or myelodysplastic syndrome MDS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2022-002432-31 | EUDRACT_NUMBER | None | None |